Systematic review and meta-analysis of the epidemiology of Lassa virus in humans, rodents and other mammals in sub-Saharan Africa.

• Published in: PLOS Neglected Tropical Diseases
• Main Authors: Sebastien Kenmoe, Serges Tchatchouang, Jean Thierry Ebogo-Belobo, Aude Christelle Ka'e, Gadji Mahamat, Raïssa Estelle Guiamdjo Simo, Arnol Bowo-Ngandji, Cynthia Paola Demeni Emoh, Emmanuel Che, Dimitri Tchami Ngongang, Marie Amougou-Atsama, Nathalie Diane Nzukui, Chris Andre Mbongue Mikangue, Donatien Serge Mbaga, Sorel Kenfack, Sandrine Rachel Kingue Bebey, Nathalie Amvongo Adjia, Atembeh Noura Efietngab, Hervé Raoul Tazokong, Abdou Fatawou Modiyinji, Cyprien Kengne-Nde, Serge Alain Sadeuh-Mba, Richard Njouom
• Format: Article in Journal/Newspaper
• Language: English
• Published: Public Library of Science (PLoS) 2020
• Subjects: Arctic medicine. Tropical medicine; RC955-962; Public aspects of medicine; RA1-1270; Arctic
• Online Access: https://doi.org/10.1371/journal.pntd.0008589; https://doaj.org/article/e1d52dff141546e79b086247a6516c87

Accurate data on the Lassa virus (LASV) human case fatality rate (CFR) and the prevalence of LASV in humans, rodents and other mammals are needed for better planning of actions that will ultimately reduce the burden of LASV infection in sub-Saharan Africa. In this systematic review with meta-analysis, we searched PubMed, Scopus, Africa Journal Online, and African Index Medicus from 1969 to 2020 to obtain studies that reported enough data to calculate LASV infection CFR or prevalence. Study selection, data extraction, and risk of bias assessment were conducted independently. We extracted all measures of current, recent, and past infections with LASV. Prevalence and CFR estimates were pooled using a random-effect meta-analysis. Factors associated with CFR, prevalence, and sources of between-study heterogeneity were determined using subgroup and metaregression analyses. This review was registered with PROSPERO, CRD42020166465. We initially identified 1,399 records and finally retained 109 reports that contributed to 291 prevalence records from 25 countries. The overall CFR was 29.7% (22.3-37.5) in humans. Pooled prevalence of LASV infection was 8.7% (95% confidence interval: 6.8-10.8) in humans, 3.2% (1.9-4.6) in rodents, and 0.7% (0.0-2.3) in other mammals. Subgroup and metaregression analyses revealed a substantial statistical heterogeneity explained by higher prevalence in tissue organs, in case-control, in hospital outbreak, and surveys, in retrospective studies, in urban and hospital setting, in hospitalized patients, and in West African countries. This study suggests that LASV infections is an important cause of death in humans and that LASV are common in humans, rodents and other mammals in sub-Saharan Africa. These estimates highlight disparities between sub-regions, and population risk profiles. Western Africa, and specific key populations were identified as having higher LASV CFR and prevalence, hence, deserving more attention for cost-effective preventive interventions.